Vimarsana
Biggest News Aggregation in the World

Page 2 - Medicines Programme News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Medicines Programme. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Medicines Programme Today - Breaking & Trending Today

NAFDAC lauds SWIPHA as W'Africa's first manufacturer to receive WHO's pre-qualification - Vimarsana News

NAFDAC lauds SWIPHA as W'Africa's first manufacturer to receive WHO's pre-qualification

The National Agency for Food, Drug Administration and Control (NAFDAC) has applauded Swiss Pharma (SWIPHA) Nigeria Limited as the World Health

NAFDAC lauds SWIPHA as 1st W/Africa manufacturer to receive WHO's pre-qualification - Vimarsana News

NAFDAC lauds SWIPHA as 1st W/Africa manufacturer to receive WHO's pre-qualification

NAFDAC has applauded Swiss Pharma (SWIPHA) Nigeria Limited as WHO pre-qualified one of the pharmaceutical company's products.

World's first generic version of COVID-19 oral drug 'PAXLOVID' receives WHO Prequalification - Vimarsana News

World's first generic version of COVID-19 oral drug 'PAXLOVID' receives WHO Prequalification

With the launch of NIRMACOM, Hetero aims to expand access of the ground-breaking antiviral in 95 LMICs including India

Welcome To IANS Live - NATION - Hetero's Covid-19 oral drug gets WHO pre-qualification - Vimarsana News

Welcome To IANS Live - NATION - Hetero's Covid-19 oral drug gets WHO pre-qualification

This is the first pre-qualification for a generic version of Pfizer's Covid-19 oral antiviral drug 'Paxlovid', which the WHO called, the best therapeutic choice for high-risk patients to date.WHO

Welcome To IANS Live - LatestNews - Hetero's Covid-19 oral drug gets WHO pre-qualification - Vimarsana News

Welcome To IANS Live - LatestNews - Hetero's Covid-19 oral drug gets WHO pre-qualification

This is the first pre-qualification for a generic version of Pfizer's Covid-19 oral antiviral drug 'Paxlovid', which the WHO called, the best therapeutic choice for high-risk patients to date.WHO